Alnylam Pharmaceuticals (ALNY) Revenue Growth (5y) (2014 - 2026)
Alnylam Pharmaceuticals (ALNY) Revenue Growth (5y) (2014 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
| 10 |
Alnylam Pharmaceuticals |
37.04 Bn |
34.03 Bn |
959.66 Mn |
| Date | Value |
|---|
| Mar 31, 2026 |
45.73% |
| Dec 31, 2025 |
46.32% |
| Sep 30, 2025 |
58.25% |
| Jun 30, 2025 |
49.40% |
| Mar 31, 2025 |
-21.32% |
| Dec 31, 2024 |
52.60% |
| Sep 30, 2024 |
48.20% |
| Jun 30, 2024 |
71.32% |
| Mar 31, 2024 |
71.53% |
| Dec 31, 2023 |
83.68% |
| Sep 30, 2023 |
225.03% |
| Jun 30, 2023 |
60.52% |
| Mar 31, 2023 |
70.90% |
| Dec 31, 2022 |
54.61% |
| Sep 30, 2022 |
72.92% |
| Jun 30, 2022 |
69.79% |
| Mar 31, 2022 |
62.26% |
| Dec 31, 2021 |
71.45% |
| Sep 30, 2021 |
68.90% |
| Jun 30, 2021 |
90.86% |
